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Rupture of abdominal aortic aneurysm (AAA)
continues to result in significant morbidity and mor-
tality.1 Since the initial reports of abdominal aortic
aneurysm repair, there has been a steady and progres-
sive decline in the mortality reported for elective
cases.2,3 Katz et al4 have noted a statewide trend for
increased numbers of elective AAA repair. However,
the frequency of ruptured AAAs (RAAAs) has not
decreased and the mortality has remained unchanged.
Population-based study results suggest that rupture of
AAA is associated with a 90% mortality, yet individual
centers report mortality rates that vary between 40%
to 70%.5-9 Analysis of these clinical series has deter-
mined many factors that contribute to the mortality in
these patients. Rapid operative intervention without
technical mishap is the current standard of therapy.10
Postoperative treatment is directed at correction of
fluid status, acid base imbalances, and hematologic
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Purpose: Ruptured abdominal aortic aneurysm (RAAA) remains a lethal condition despite
improvements in perioperative care. The consequences of RAAA are hypothesized to result
from a combination of two ischemia/reperfusion events: hemorrhagic shock and lower
torso ischemia. Ischemia/reperfusion results in tissue injury by diverse mechanisms, which
include oxygen free radical–mediated injury produced from activated neutrophils, xanthine
oxidase, and mitochondria. Oxygen-free radicals attack membrane lipids, resulting in
membrane and subsequently cellular dysfunction that contributes to postoperative organ
injury/failure. The purpose of this investigation was to quantify the oxidative injury that
occurs as a result of the ischemia/reperfusion events in RAAAs and elective AAAs.
Methods: Blood samples were taken from 22 patients for elective AAA repair and from 14
patients for RAAA repair during the perioperative period. Plasma F2-isoprostanes were
extracted, purified, and measured with an enzyme immunoassay. Aldehydes and acyloins
were purified and quantified. Neutrophil oxidative burst was measured in response to a
receptor independent stimulus (phorbol 12-myristate 13-acetate) with luminol-based
chemiluminescence.
Results: Plasma from patients with RAAAs showed significantly elevated F2-isoprostane
levels on arrival at hospital and were significantly elevated as compared with the levels of
patients for elective repair throughout the perioperative period (two-way analysis of vari-
ance, P < .0001). Multiple regression showed a significant relationship between the
phagocyte oxidative activity and F2-isoprostane levels (P < .013). Total acyloin levels were
significantly higher in patients with RAAAs as compared with the levels in elective cases.
Conclusion: The F2-isoprostane levels, specific markers of lipid peroxidation, showed
that patients with RAAAs had two phases of oxidative injury: before arrival at hospital
and after surgery. The significant relationship between the postoperative increases in F2-
isoprostane levels and the neutrophil oxidant production implicates neutrophils in the
oxidative injury that occurs after RAAA. New therapeutic interventions that attenuate
neutrophil-mediated oxidant injury during reperfusion may decrease organ failure and
ultimately mortality in patients with RAAAs. (J Vasc Surg 1999;30:219-28.)
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deficiencies. However, no specific treatments have
been developed to decrease the mortality from the
cardiovascular events or from the multiple organ fail-
ure that frequently develops.11 Improvements in peri-
operative care have not resulted in dramatic improve-
ments in mortality.12
The principle difference between elective and
RAAA repair is the period of hemorrhagic shock.
Animal studies have established that hemorrhagic
shock with resuscitation is a total body ischemia/
reperfusion event.13 All aneurysm repairs experience
lower torso ischemia induced by aortic clamp applica-
tion.14 Is it possible that these two ischemia reperfu-
sion events act synergistically in patients with RAAAs
to induce the organ failure and mortality observed?
Tissue or organ ischemia, which is prolonged and
followed by reperfusion, will result in organ injury
and dysfunction.15 The severity of injury is depen-
dent on many factors, which include the degree and
duration of the ischemic insult and the sensitivity of
the individual tissue to ischemia. During ischemia,
the lack of oxygen leads to anaerobic metabolism and
depletion of energy stores, which may ultimately fail
to meet the tissue energy requirements. Once the
energy stores are depleted, membrane ion gradients
begin to fail, membranes leak, cells swell, and the
process of irreversible injury begins. Reperfusion
restores tissue oxygenation but initiates an inflamma-
tory response that has been shown to cause further
tissue injury.16-18 The xanthine/xanthine oxidase
system, activated neutrophils, and mitochondrial
electron transport chain leakage are documented
sources of activated oxygen species during reperfu-
sion.19 These activated oxygen species and their
metabolites (superoxide O2–, hydrogen peroxide
H2O2, hypochlorus acid HOCl, and hydroxyl radi-
cals OH–) react with unsaturated fatty acids within
the phospholipid bilayer of the cell membrane,
resulting in lipid peroxidation. Oxidant-mediated
injury is detected with measurement of lipid peroxi-
dation products, such as malondialdehyde and other
aldehydes, lipid hydroperoxides, conjugated dienes,
and acyloins. Cleavage of the long-chain fatty acids
after lipid peroxidation results in fragmentation
products, which add oxygen and result in the pro-
duction of aldehydes. The spectrum of aldehydes of
various carbon chain lengths can be formed.
However, they react rapidly and are quickly cleared
from the circulation.20 Aldehydes are detoxified by
several mechanisms, including one in which com-
pounds called acyloins are formed by the pyruvate
dehydrogenase complex, resulting in the addition of
a two-carbon fragment to saturated aldehydes.21
Recently, the F2-isoprostanes were discovered to be
markers of oxidant injury.22 These prostaglandin-like
compounds are formed from free-radical catalyzed
peroxidation of arachadonic acid through a non-
cyclooxygenase enzyme pathway.22 These unique
products can be measured and appear to be a sensi-
tive and specific measure of free radical activity in sev-
eral models of oxidant injury.23-25 Therefore, the
measurement of F2-isoprostanes, aldehydes, and
acylions will permit an assessment of oxidative lipid
peroxidation in patients with RAAAs.
The purpose of this investigation was to quanti-
fy oxidative injury caused by the ischemia/reperfu-
sion events in RAAAs and elective AAAs. Secondly, a
relationship was sought between the recently identi-
fied primed neutrophil oxidative burst of patients for
both elective repair and RAAA repair and the quan-
tity of lipid oxidative products identified.
METHODS
Informed consent for blood sampling was
obtained from patients for elective and RAAA repair
in accordance with the Toronto Hospital and
University of Toronto Human Subject Research
Committee’s requirements. Blood samples were har-
vested from the arterial line, central venous line, or
a peripheral vein according to a preset sampling pro-
tocol previously described.26 Blood samples were
taken: (1) before induction of anesthesia, (2) before
cross-clamp application, (3) before clamp removal,
and (4) at 15, 60, and 240 minutes after clamp
removal. Further samples (samples 1 to 7) were
taken on a daily basis. Blood was harvested into 7-
mL sterile lavender vacutainer tubes that contained
10.5 mg ethylenediamine tetraacetic acid (EDTA)
and 0.014 mg potassium sorbate in 0.07 mL of 15%
EDTA solution (Becton Dickinson, Franklin Lakes,
NJ). The samples were kept at room temperature
and were rapidly transported to the laboratory for
analysis. The samples were gently rocked (Blood
Rocker Model R4185-10, Baxter, Deerfield, Ill) for
several minutes before an aliquot was removed for
analysis of whole blood chemiluminescence and an
automated complete differential blood count. The
blood then was rapidly cooled to 4°C and cen-
trifuged at 1800g for 15 minutes. The plasma was
decanted into polypropylene tubes, snap frozen, and
stored at –70oC. The aliquot of whole blood for
chemiluminescence was measured at 37oC in an
Autoluminat LB953 Luminometer with reagents
from ExOxEmis Inc (Little Rock, Ark). Each assay
was performed in triplicate with whole blood dilut-
ed 1/1000 with buffer and 7.1 m mol/L phorbol 12-
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myristate 13-acetate (PMA) added to the luminol.
Chemiluminescence was measured for a 30-minute
period, and the area under the curve was integrated.
F2-isoprostane measurement. Frozen plasma
(0.5 mL) was thawed, and 5000 disintegrations per
minute (dpm) of an internal standard (tritium labeled
PGF2a ) was added to quantify recovery during purifi-
cation. Plasma protein were precipitated with ethanol
and removed with centrifugation. F2-isoprostanes and
all other fatty acid side chains were removed from the
glycerol backbone by KOH hydrolysis at 40oC. The
pH was adjusted to less than 4 with HCl, and the solu-
tion was loaded onto an activated reverse phase C18
Sep-Pak Column (Waters Inc, Mississauga, Ontario).
The column was washed with Ultrapure water
(Millipore, Mississauga, Ontario) and hexane. F2-
isoprostanes were eluted with ethyl acetate:methanol
(99:1), evaporated to dryness under dry nitrogen, and
stored under nitrogen at –70oC until further analysis.
The samples were analyzed in duplicate for F2-iso-
prostane content with a commercially available
enzyme-linked 8-isoprostane immunoassay (Cayman
Chemical Co, Ann Arbor, Mich). Recovery from the
purification step was analyzed with scintillation count-
ing of the extract with Aquasol (Canberra-Packard
Instruments, Meridan, Conn). The recovery range was
always greater than 80%, and this was factored into the
calculation. F2-isoprostanes values are expressed as
pg/mL of plasma.
Aldehyde and acylion measurement. The alde-
hydes and acyloins in a 100-m L plasma sample were
derivitized with O-2,3,4,5,6-pentafluorobenzyl
hydroxylamine hydrochloride and incubated at room
temperature for 30 minutes. The protein was precip-
itated with methanol, and hexane was added fol-
lowed by acidification with concentrated sulphuric
acid. After centrifugation at 3000 rpm, the hexane
layer was removed, dried over sodium sulphate, and
evaporated under nitrogen. The N,O-bis(trimethylsi-
lyl)trifluoroacetamide reagent was added followed by
incubation at 80oC to form trimethylsilyl ethers. A 1-
m L sample was injected into the gas chromatography
mass spectrometry (GC-MS).
Capillary action column gas chromatography with
negative ion chemical ionization mass spectrometry
(GC-NICIMS) and ammonia as the reagent gas 
was used to analyze the pentafluorobenzyl-oxine-
trimethylsilyl derivatives. This was performed in a
high-sensitivity, research-grade quadrupole mass spec-
trometer (VG-Trio 2A) with an interface to a Hewlett
Packard 5890 series II gas chromatograph (Miss-
issauga, Ontario) equipped with a 30-m, 0.25- m m,
DB-5 column (S & W Scientific, Folsom, Calif). The
temperature of the injection port was at 250oC, and
the column temperature was initially set at 60oC for 1
minute, was increased by 20oC per minute until
85oC, and then was raised 8oC per minute to 310oC.
A specific ion for each derivative was chosen for select-
ed-ion recording. The detection limits were between
50 and 100 fmol per 1 m L injected. Concentrations in
the biologic samples were calculated from the ratio of
peak height as compared with pure aldehydes and acy-
loin standards that had been injected. Results are
expressed in nmol/L of plasma. This method is sensi-
tive and completely specific for aldehyde and acyloin
analysis caused by the precise identification afforded
by the GC-NICIMS technology.
In vitro production of F2-isoprostanes in acti-
vated neutrophils. Neutrophils were purified from
healthy human volunteers with a percoll-hypaque
gradient and differential centrifugation. The neu-
trophils were 95% pure by differential counting and
98% viable by trypan blue exclusion. After Coulter
counter determination of the neutrophil concentra-
tion, cells were diluted to 1 · 106/mL. The neu-
trophils were added to an equal volume of 10%
platelet-poor autologous plasma and incubated with
or without PMA (100 nmol/L) for 30 minutes.
PMA is a phorbol ester that stimulates neutrophil
oxidative burst by diffusing across the cell mem-
brane and directly stimulates protein kinase C with-
out necessitating membrane receptors. The samples
were rapidly cooled to 4oC and centrifuged to pre-
cipitate the neutrophils. The supernatant and neu-
trophils were extracted for F2-isoprostanes content
as previously described and were analyzed with the
immunoassay. All the experiments were performed
in duplicate, and the results were averaged. The
results are expressed as pg F2-isoprostanes/1 · 106
neutrophils and per 2 mL of supernatant.
Statistical analysis. Data were analyzed with the
SAS (SAS Institute, Inc, Cary, NC) for PC statistical
program, with Sigma Stat (SPSS Inc, Chicago, Ill), or
with both. Continuous data were compared with uni-
variate t test analysis. The main effects of group (elec-
tive vs RAAA), time (time course of measurements
during and after AAA repair), and their interaction
(group*time) were evaluated with two-way analysis of
variance (ANOVA) for the dependent variables: F2-
isoprostanes, and neutrophil oxidant burst measured
with chemiluminescence. The relationship between
chemiluminescence and F2-isoprostanes, time and
group, was also evaluated with an analysis of covari-
ance. A multiple linear regression with forward selec-
tion combined with backward elimination was per-
formed to identify the independent predictors of F2-
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isoprostane levels. For measures that were repeated
over the time course of AAA repair, a one-way repeat-
ed measures ANOVA (RM-ANOVA) was used with
comparison to the pre-induction sample (PI) with
Dunnett test to correct for multiple comparisons.
The results are presented as means ± standard
errors in the text, tables,and figures. The results
were considered statistically significant if the P value
was less than .05.
RESULTS
The lower torso ischemia/reperfusion necessitat-
ed for elective AAA repair did not result in any sig-
nificant alteration in plasma F2-isoprostane levels in
the perioperative period. The levels of this marker of
oxidant injury in these patients for elective AAA
repair were slightly higher than the range reported
for control groups in the literature (pre-induction
56.0 ± 8.9 pg/mL compared with literature normals
35 ± 6 pg/mL; Fig 1). This is a relatively small dif-
ference given the differences in measurement tech-
nique (radioimmunoassay vs mass spectrometry) and
that our sample was of patients who underwent elec-
tive aneurysm surgery. In contrast, in patients with
RAAAs, the levels of F2-isoprostane were elevated
before surgical intervention 109.5 ± 16.5 pg/mL as
compared with elective 56.0 ± 8.9 pg/mL (P < .01,
with t test). The levels in patients with RAAAs
remained significantly elevated through the periop-
erative period, and further significant increases were
noted on the third and fifth days after surgery in the
RAAAs as compared with the preclamp release sam-
ple (109.6 ± 46.5 pg/mL vs 154.4 ± 20.3 pg/mL;
P < .05, with RM-ANOVA, and P < .05, with
Dunnett test; day 5). A two-way ANOVA on the
combined elective and RAAA repair F2-isoprostane
data set identified that both group and time were
significant main effects. The interaction term
(group*time) was also significant (P < .016), which
identifies a significantly different rate of change in
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Fig 1. Plasma F2-isoprostanes in elective and ruptured abdominal aortic aneurysm repair.
Plasma levels of F2-isoprostane measured during perioperative period for elective and ruptured
aneurysms at indicated time points. Two-way analysis of variance showed significant group,
time, and group*time effects.
PI, Pre induction of anesthesia; PR, pre release of aortic clamp; 15 MIN, 15 minutes after
clamp removal; 1 HR, 1 hour after clamp removal; D1, first postoperative day; D3, third post-
operative day; D5, fifth postoperative day; EAAA, elective abdominal aortic aneurysm repair;
RAAA, ruptured abdominal aortic aneurysm repair. Repeated measures analysis of variance for
both groups, P < .001.
the F2-isoprostane levels between the two groups.
An analysis of covariance with the natural log trans-
formation of the F2-isoprostane levels revealed a sig-
nificant group and time interaction (P < .001),
which is further statistical evidence that the slopes,
or the rate of change between the two groups over
time, was different (R2 = 0.165; P = .001). We con-
firmed the ANOVA result with a multiple linear
regression, which showed a significant association
between neutrophil oxidative burst (chemilumines-
cence PMA), group, time, and the natural log of F2-
isoprostane (R2 = 0.32; P = .013; Fig 2; oxidant pro-
duction by neutrophils from patients with AAAs was
previously published). No significant relationship
was noted within each group (RAAA: R2 = 0.001; P
= .71; EAAA: R2 = 0.004; P = .36).
Aldehyde and acylion measurements. The
entire spectrum of aldehydes and acyloins was mea-
sured in both groups of patients with aneurysm. No
differences in aldehyde levels between the two
groups were noted (PI level, EAAA: 125.0 ± 6.4
pg/mL vs RAAA: 138.9 ± 17.1 pg/mL; at 15 min-
utes, 124.5 ± 8.05 vs 142.5 ± 18.6; at 1 hour, 116.2
± 7.4 vs 117.2 ± 7.6). Fig 3 shows the alterations in
the sum of all the acyloins (aldehyde detoxification
products) in both groups during the early postoper-
ative period, which were measured with GC-
NICIMS. The group of elective AAA repair shows a
slow rise in the total acyloin content, which became
significant on the first postoperative day (RM-
ANOVA, P < .0002; Dunnett test, P < .05, day 1 vs
PI). In the RAAAs, the rise in acyloin level was
apparent within 15 minutes of clamp release, but
this was not statistically significant. By the first post-
operative day, a near doubling of the total plasma
acyloins was noted in the RAAA group, which was
significant, as compared with the preinduction levels
(RM-ANOVA, P < .005; Dunnett test, P < .05, day
1 vs PI). The patients with RAAAs had significantly
higher levels of total plasma acyloin content as com-
pared with the patients for elective repair both at 1-
hour post–aortic clamp removal and at the first post-
operative day.
The acyloin, 3-hydroxynonan-2-one, is derived
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Fig 2. Relationship between stimulated neutrophil oxidative burst and index of oxidant injury
over time. Linear relationship between stimulated neutrophil oxidative burst (chemilumines-
cence phorbol 12-myristate 13-acetate [PMA]) and level of F2-isoprostanes measured in plasma
at that time point for patients for both elective and ruptured abdominal aortic aneurysm repair.
Regression line calculated for entire data is F2-isoprostane level = 40.536 + 0.0042498 (PMA
stimulated chemiluminescence). Regression line and slope for each group was significantly dif-
ferent. However, overall line is shown to simplify the figure. Numbers beside each data point
represent time at which each sample was taken (samples 1 to 6 were taken on day of operation,
and samples 7 to 11 were taken daily for first 5 postoperative days). Each point is mean of F2-
isoprostane level plotted against neutrophil oxidant burst measured by chemiluminescence.
from the fusion of heptanal and pyruvate and shows
a pattern of oxidative injury characterized by a dif-
ference noted before surgery and further progressive
increases, which become significant 1 hour after aor-
tic clamp removal (Fig 4). This acyloin (which is one
of the acyloins included in the data represented in
Fig 3) slowly increases in the elective AAAs, with sig-
nificant increases noted at 1 hour and on the first
postoperative day as compared with the preinduc-
tion level. The patients with RAAAs showed signifi-
cant elevations of 3-hydroxynonan-2-one as com-
pared with the patients for elective surgery at all time
points measured (P < .01, RAAA vs EAAA).
In vitro production of F2-isoprostanes by
activated neutrophils. Unstimulated and stimulat-
ed neutrophils were tested in vitro to determine
whether activated neutrophils resulted in increased
quantities of F2-isoprostane being produced.
Neutrophils stimulated with PMA for 30 minutes
significantly increased the total content of F2-iso-
prostane (unstimulated 103.6 ± 4.9 pg/mL vs PMA
stimulated 146.7 ± 10.3 pg/mL, P = .001; Table I).
The increase in F2-isoprostanes content was mainly
in the neutrophil fraction of the stimulated cells
(unstimulated 53.2 ± 4.3 vs PMA stimulated 78.8 ±
8.1; P = .01). The rise in the F2-isoprostane content
of the supernatant failed to reach significance (50.4
± 2.6 vs 67.8 ± 7.3; P = .14).
DISCUSSION
This study examined two independent indices of
lipid peroxidation, F2-isoprostanes and acyloins/alde-
hydes, in the plasma of patients for elective and RAAA
repair. Alterations in the circulating levels of these
lipid peroxidation products are indices of free-radical
generation and tissue injury.27 Free radicals are gener-
ated at increased rates during reperfusion after
ischemic events. Thus, identification of increases in
circulating levels of lipid peroxidation products
reflects the magnitude of systemic free-radical tissue
injury that develops after ischemic events.
A reliable method to detect and quantify lipid
peroxidation for in vitro and in vivo use has long
been sought. Early measurements of lipid peroxida-
tion were directed at malondialdehyde quantifica-
tion via measurement of thiobarbituric acid reactive
substances. Malondialdehyde measurements were
found to lack sensitivity and specificity, and thus
researchers directed their efforts at the measurement
of intermediates of oxidative injury that were much
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Fig 3. Total plasma acyloins. Total acyloin content of plasma is represented. Repeated mea-
sures analysis of variance for both groups, P < .001.
*P < .05 vs pre-induction sample value.
+P < .05 elective abdominal aortic aneurysm repair vs ruptured abdominal aortic aneurysm
repair. 
more proximal in the chain reaction of events.
Elevated conjugated dienes were measured in skele-
tal and cardiac muscle after ischemia/reperfusion
injury that provided evidence of lipid peroxidation.
However, they are technically difficult to mea-
sure.28,29 Aldehydes are formed by lipid peroxida-
tion and cleavage from fatty acids within cellular
membranes. Recently, a method to measure all alde-
hydes and acyloins has been described.20 Several
groups have measured aldehyde-protein fusion
products to identify and quantify peroxidation injury
after ischemia/reperfusion.21 Acyloins are derived
from the addition of pyruvate to a reactive aldehyde
via the pyruvate dehydrogenase complex. The heart
has been shown to be a potential site of this reaction.
The measurement of F2-isoprostanes is the most
recent development in the lipid peroxidation field.27
These products result from free radical attack on
arachadonic acid.25 This results in the formation of
a stable five-member ring with striking similarity to
the prostaglandin F2 a family. These compounds
were initially detected and quantified with GC-MS,
with detection of the negative ion chemical ioniza-
tion products. The immunoassay used in this study
has been shown to correlate well with the results of
the GC-MS analysis. Investigations have determined
that only minimal amounts of F2-isoprostane are
produced via a cyclooxygenase pathway and that the
vast majority are caused by free-radical injury.30,31 In
a model of carbon tetrachloride–induced free-radical
injury, F2-isoprostanes were detected initially in the
membranes of liver tissue.32 This was followed by a
progressive release of F2-isoprostanes into the plas-
ma, where their half life was found to be 16 minutes.
Recently, increased levels of F2-isoprostane have
been identified in patients with acute myocardial
infarction treated with thrombolytic therapy.33
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Fig 4. 3-Hydroxynona-2-one plasma levels. Repeated measures analysis of variance for both
groups, P < .001.
*P < .05 vs pre-induction sample value.
+P < .05 elective abdominal aortic aneurysm repair vs ruptured abdominal aortic aneurysm
repair.
Table I. The F2-isoprostane levels from the super-
natant, human neutrophil, and total content after
in vitro activation of oxidant burst with PMA at 
30 minutes
Unstimulated PMA Stimulated
Supernatant 50.4 ± 2.6 67.8 ± 7.3
Neutrophil 53.2 ± 4.3 78.8 ± 8.1 *
Total 103.6 ± 4.9 146.7 ± 10.3 +
PMA, Phorbol 12-myristate 13-acetate.
*P = .01 compared with unstimulated.
+P = .001 compared with unstimulated.
Animal experiments with myocardial ischemia have
also shown similar results.34 These and other exper-
iments have established F2-isoprostane as the cur-
rent gold standard for measurement of oxidative tis-
sue injury.
Diverse mechanisms and mediators that include
neutrophils, the xanthine/xanthine oxidase enzyme
system, and mitochondrial electron transport leakage
cause oxidant-mediated tissue injury after ischemia
reperfusion.35 Ischemia with or without reperfusion is
a central mechanism of local and remote tissue injury
in many human diseases, which include myocardial
infarction, stroke, embolic vascular organ or limb
occlusions, trauma, and hemorrhagic shock. The
detection of lipid peroxidation products implicates an
oxygen-free radical mechanism of injury.
The F2-isoprostane results show, for the first
time, that the individual events that comprise repair
of an RAAA (shock and lower torso ischemia) each
result in significant elevations of lipid peroxidation
products. The elevated levels of F2-isoprostane noted
before surgical repair in the RAAAs identifies that the
“first hit” of the oxidative injury had begun before
arrival at the hospital. The further significant increas-
es noted after surgery appear to be caused by the
combination of hypotension and lower torso
ischemia. We noted that RAAA repair, which necessi-
tates lower torso ischemia, induces a second phase of
significant elevations in postoperative F2-isoprostanes
levels. This second rise in F2-isoprostanes is noted on
third and fifth postoperative days and is evidence of
postoperative oxidative injury—“a second hit.”
When our results are compared with single-hit
events, these injuries have a monophasic elevation in
F2-isoprostanes.33,34 In studies of patients with
myocardial ischemia, the urinary metabolites of F2-
isoprostane became elevated and fell rapidly.33,34
Animal studies also show rapid clearance of F2-iso-
prostanes from the circulation after a single oxidative
event.33 In elective AAA repairs, lower torso ischemia
alone did not result in a rise in F2-isoprostanes. Thus,
the significant postoperative increases in the RAAA
group suggest ongoing postoperative oxidative
injury and thus provide evidence of a “two-hit”
injury. Measurements of plasma acyloins, a second
specific marker of lipid peroxidation, also show a
larger degree of oxidative injury in the patients with
RAAAs as compared with the elective repair group.
Alterations in aldehyde levels may have been so tran-
sient that measurement of differences between
groups was precluded because of rapid detoxification.
The significant relationship between stimulated
neutrophil oxidant activity and the postoperative
levels of F2-isoprostane suggest a significant mecha-
nistic link between these two events (Fig 2).
Neutrophils are critical mediators of tissue injury
after ischemia reperfusion events. However, they are
by no means the exclusive cause of lipid peroxidation
injury.35,36 Although other mechanisms of oxidative
injury are clearly operational, stimulated neutrophil
oxidative burst is likely a significant mediator of this
injury. The enhanced production of F2-isoprostane
in vitro by stimulated neutrophils shows that the
oxidative burst of these cells can be responsible for
production of these lipid peroxidation products.
These in vitro data lend support to the mathematic
relationship that we have demonstrated between the
stimulated neutrophil oxidative burst and the plasma
level of F2-isoprostanes.
Overall, the oxidative injury caused by lower
torso ischemia/reperfusion in patients for elective
repair is modest. The elevation in postoperative acy-
loin levels suggests that an increase in lipid peroxi-
dation develops early in the postoperative phase of
elective AAA repair. This level of oxidative injury
appears to be insufficient to increase F2-isoprostane
levels. This is in keeping with the low incidences of
organ failure and mortality that follow elective AAA
repair.37
Recently, hemorrhagic shock and resuscitation
have been recognized as a whole body ischemia/
reperfusion type injury.13 A dramatic reduction in
organ injury and mortality was observed when an
antibody against the neutrophil CD18 adhesion
receptor, which prevents firm neutrophil adhesion,
was administered during resuscitation in a model of
hemorrhagic shock.38 During resuscitation from
hemorrhagic shock, the no-reflow phenomenon has
been documented and neutrophil adhesion in the
capillaries has been described.39 Taken together, these
studies support the hypothesis that shock and resusci-
tation causes neutrophil activation. Also, prolonged
lower torso ischemia by itself has been documented to
result in local and remote organ injury.14,40 Our
results support the conclusion that each of these indi-
vidual ischemia/reperfusion events results in oxidative
tissue injury after repair of RAAA. The combined
insult results in a systemic oxidative injury that chal-
lenges the function of every organ. Our observations
suggest that therapeutic interventions directed at the
oxidative injury, even if provided after the period of
hypotension during the operative repair of an RAAA,
may prevent further tissue injury.
In summary, this study has identified two phases
of oxidative ischemia/reperfusion injury in those
patients who undergo repair of RAAA with two spe-
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cific and sensitive markers of lipid peroxidation. The
F2-isoprostane results suggest a “two-hit” model of
injury induced by hemorrhagic shock followed by
lower torso ischemia in patients with RAAAs.
Neutrophils have been shown to be activated by
both phases of RAAA.26 The relationship between
the F2-isoprostane levels and the oxidant production
activity of the patient’s neutrophils suggests a role
for neutrophil-induced oxidative tissue injury after
RAAA. Treatments directed at preventing neu-
trophil activation or adhesion, or the scavenging of
activated oxygen species, may reduce organ injury
and mortality after RAAA repair.
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